Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study
DOI:
https://doi.org/10.2340/actadv.v103.13475Keywords:
Alopecia Areata, Tofacitinib, JAK inhibitor, Drug Survival, effectivenessAbstract
Several non-randomized clinical trials and retrospective studies have demonstrated encouraging efficacy and well-tolerated safety of tofacitinib in the treatment of alopecia areata. However, there are scarce data on a large cohort of patients with alopecia areata in long-term real-world practice. This single-centre, retrospective, observational cohort study included 126 patients with alopecia areata treated with tofacitinib between February 2021 and December 2022. The aims of this study are to evaluate drug survival, effectiveness and safety of tofacitinib for treatment of alopecia areata, and to identify potential factors influencing long-term outcomes. Median duration of treatment was 23.00 (interquartile range (IQR) 15.00, 47.25) weeks. Median all-cause survival time of 126 patients treated with tofacitinib was 44 weeks (95% confidence interval (95% CI) 36.3, 51.7), and the all-cause drug retention rate at 12 weeks, 24 weeks and 48 weeks were 90.0%, 66.4% and 42.3%, respectively. The most common reason for discontinuation was complete remission/satisfaction. A total of 80 patients treated with tofacitinib for over 6 months were included in the efficacy analysis, the overall complete response rate at 24 weeks was 33.8% (27/80). No life-threatening serious adverse events occurred. Sex is an independent risk factor in predicting patient outcomes. This real-world study confirmed the high effectiveness and acceptable safety profile of tofacitinib in alopecia areata, with a satisfactory drug survival rate, and provides supporting data for the clinical application of tofacitinib in Chinese patients with alopecia areata.
Downloads
References
Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med 2012; 366: 1515-1525.
https://doi.org/10.1056/NEJMra1103442 DOI: https://doi.org/10.1056/NEJMra1103442
Mostaghimi A, Gao W, Ray M, Bartolome L, Wang T, Carley C, et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. JAMA Dermatol 2023; 159: 411-418.
https://doi.org/10.1001/jamadermatol.2023.0002 DOI: https://doi.org/10.1001/jamadermatol.2023.0002
Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018; 78: 1-12.
https://doi.org/10.1016/j.jaad.2017.04.1141 DOI: https://doi.org/10.1016/j.jaad.2017.04.1141
Lensing M, Jabbari A. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata. Front Immunol 2022; 13: 955035.
https://doi.org/10.3389/fimmu.2022.955035 DOI: https://doi.org/10.3389/fimmu.2022.955035
Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 2017; 76: 736-744.
https://doi.org/10.1016/j.jaad.2016.12.005 DOI: https://doi.org/10.1016/j.jaad.2016.12.005
Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 2017; 76: 22-28.
https://doi.org/10.1016/j.jaad.2016.09.007 DOI: https://doi.org/10.1016/j.jaad.2016.09.007
Sanchez-Diaz M, Diaz-Calvillo P, Rodriguez-Pozo JA, Tercedor-Sánchez J, Cantudo-Cuenca MR, Molina-Leyva A, et al. Tofacitinib for treatment of alopecia areata: real-world evidence and factors associated with therapeutic response. Acta Derm Venereol 2022; 102: adv00736.
https://doi.org/10.2340/actadv.v102.2036 DOI: https://doi.org/10.2340/actadv.v102.2036
Park HS, Kim MW, Lee JS, Yoon HS, Huh CH, Kwon O, et al. Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series. J Am Acad Dermatol 2017; 77: 978-980.
https://doi.org/10.1016/j.jaad.2017.06.027 DOI: https://doi.org/10.1016/j.jaad.2017.06.027
AlMarzoug A, AlOrainy M, AlTawil L, AlHayaza G, AlAnazi R, AlIssa A, et al. Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population. Int J Dermatol 2022; 61: 886-894.
https://doi.org/10.1111/ijd.15917 DOI: https://doi.org/10.1111/ijd.15917
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet 2023; 401: 1518-1529.
https://doi.org/10.1016/S0140-6736(23)00222-2 DOI: https://doi.org/10.1016/S0140-6736(23)00222-2
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 2022; 386: 1687-1699.
https://doi.org/10.1056/NEJMoa2110343 DOI: https://doi.org/10.1056/NEJMoa2110343
King BA, Craiglow BG. Janus kinase inhibitors for alopecia areata. J Am Acad Dermatol 2023; 89: S29-s32.
https://doi.org/10.1016/j.jaad.2023.05.049 DOI: https://doi.org/10.1016/j.jaad.2023.05.049
Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 2018; 178: 509-519.
https://doi.org/10.1111/bjd.16102 DOI: https://doi.org/10.1111/bjd.16102
Guo L, Feng S, Sun B, Jiang X, Liu Y. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol 2020; 34: 192-201.
https://doi.org/10.1111/jdv.15937 DOI: https://doi.org/10.1111/jdv.15937
Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 2021; 80: 71-87.
https://doi.org/10.1136/annrheumdis-2020-218398 DOI: https://doi.org/10.1136/annrheumdis-2020-218398
Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines - Part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004; 51: 440-447.
https://doi.org/10.1016/j.jaad.2003.09.032 DOI: https://doi.org/10.1016/j.jaad.2003.09.032
Taneja N, Gupta S. Apremilast is efficacious in refractory alopecia areata. J Dermatolog Treat 2020; 31: 727-729.
https://doi.org/10.1080/09546634.2019.1616046 DOI: https://doi.org/10.1080/09546634.2019.1616046
van den Reek J, Kievit W, Gniadecki R, Goeman JJ, Zweegers J, van de Kerkhof PCM, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol 2015; 135: 1-5.
https://doi.org/10.1038/jid.2015.171 DOI: https://doi.org/10.1038/jid.2015.171
Jung JY, Lee E, Kim JW, Suh CH, Kim HA. Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry. Clin Exp Rheumatol 2023; 41: 1034-1041.
https://doi.org/10.55563/clinexprheumatol/6fcyza DOI: https://doi.org/10.55563/clinexprheumatol/6fcyza
Zhang W, Li X, Chen B, Zhang J, Torres-Culala KMT, Zhou C. Oral tofacitinib and systemic corticosteroids, alone or in combination, in patients with moderate-to-severe alopecia areata: a retrospective study. Front Med (Lausanne) 2022; 9: 891434.
https://doi.org/10.3389/fmed.2022.891434 DOI: https://doi.org/10.3389/fmed.2022.891434
Jabbari A, Sansaricq F, Cerise J, Chen JC, Bitterman A, Ulerio G, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Invest Dermatol 2018; 138: 1539-1545.
https://doi.org/10.1016/j.jid.2018.01.032 DOI: https://doi.org/10.1016/j.jid.2018.01.032
Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol 2021; 61: 403-423.
https://doi.org/10.1007/s12016-021-08883-0 DOI: https://doi.org/10.1007/s12016-021-08883-0
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016; 16: 626-638.
https://doi.org/10.1038/nri.2016.90 DOI: https://doi.org/10.1038/nri.2016.90
Sandborn WJ, Su C, Panes J. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 377: 496-497.
https://doi.org/10.1056/NEJMc1707500 DOI: https://doi.org/10.1056/NEJMc1707500
Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet 2021; 398: 1984-1996.
https://doi.org/10.1016/S0140-6736(21)01255-1 DOI: https://doi.org/10.1016/S0140-6736(21)01255-1
Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2021; 80: 1004-1013.
https://doi.org/10.1136/annrheumdis-2020-219601 DOI: https://doi.org/10.1136/annrheumdis-2020-219601
Taneja V, El-Dallal M, Haq Z, Tripathi K, Systrom HK, Wang LF, et al. Effectiveness and safety of tofacitinib for ulcerative colitis: systematic review and meta-analysis. J Clin Gastroenterol 2022; 56: e323-e333.
https://doi.org/10.1097/MCG.0000000000001608 DOI: https://doi.org/10.1097/MCG.0000000000001608
Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol 2022; 18: 301-304.
https://doi.org/10.1038/s41584-022-00767-7 DOI: https://doi.org/10.1038/s41584-022-00767-7
Ozdede A, Yazıcı H. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022; 386: 1766.
https://doi.org/10.1056/NEJMc2202778 DOI: https://doi.org/10.1056/NEJMc2202778
Yan D, Fan H, Chen M, Xia L, Wang S, Dong W, et al. The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies. Front Pharmacol 2022; 13: 950450.
https://doi.org/10.3389/fphar.2022.950450 DOI: https://doi.org/10.3389/fphar.2022.950450
Akada H, Akada S, Hutchison RE, Sakamoto K, Wagner KU, Mohi G. Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells. Stem Cells 2014; 32: 1878-1889.
https://doi.org/10.1002/stem.1711 DOI: https://doi.org/10.1002/stem.1711
Miyake M, Goodison S, Lawton A, Zhang G, Gomes-Giacoia E, Rosser CJ. Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions. J Hematol Oncol 2013; 6: 65.
https://doi.org/10.1186/1756-8722-6-65 DOI: https://doi.org/10.1186/1756-8722-6-65
Hao XR, Cao DL, Hu YW, Li XX, Liu XH, Xiao J, et al. IFN-gamma down-regulates ABCA1 expression by inhibiting LXRalpha in a JAK/STAT signaling pathway-dependent manner. Atherosclerosis 2009; 203: 417-428.
https://doi.org/10.1016/j.atherosclerosis.2008.07.029 DOI: https://doi.org/10.1016/j.atherosclerosis.2008.07.029
Additional Files
Published
How to Cite
License
Copyright (c) 2023 Jundong Huang, Sihan Deng, Ji Li, Yan Tang, Fangfen Liu, Yu Liu, Shijia Rao, Wei Shi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
